Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the development of next-generation anti-obesity medication...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wael R. Sidrak, Sanjay Kalra, Atul Kalhan
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-11-01
Series:	Indian Journal of Endocrinology and Metabolism
Subjects:	amylin anti-obesity medication dual receptor agonists glucagon glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide obesity peptide tyrosine-tyrosine triple receptor agonists weight management
Online Access:	https://journals.lww.com/10.4103/ijem.ijem_442_23
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)

The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and ratsResearch in context
by: Rune Ehrenreich Kuhre, et al.
Published: (2025-08-01)

Gut Hormones and Inflammatory Bowel Disease
by: Jonathan Weng, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment
by: Se-Eun Kim, et al.
Published: (2025-05-01)

Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide
by: Yuki Oe, et al.
Published: (2025-05-01)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01)

Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics
by: David Vogrinc, et al.
Published: (2024-10-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis
by: Bashaier Al-Zaid, et al.
Published: (2025-03-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes
by: Anna A Mosikian, et al.
Published: (2022-03-01)

Semaglutide and the Retina
by: Zachary T. Bloomgarden
Published: (2025-04-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

The hidden impact of GLP‐1 receptor agonists on endometrial receptivity and implantation
by: Alberto Sola‐Leyva, et al.
Published: (2025-02-01)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01)

Adipocytokine levels in patients with atherosclerosis and high triglyceride – glucose index
by: E. V. Garbuzova, et al.
Published: (2024-10-01)

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes
by: Qiumei Zhang, et al.
Published: (2025-05-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide
by: Mark L. Hartman, et al.
Published: (2025-08-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

The role of GIPR in food intake control
by: Paula-Peace James-Okoro, et al.
Published: (2025-03-01)

Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes
by: Akinori Hayashi, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
by: Yosra Turkistani
Published: (2025-04-01)

Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study (CONVERGE)
by: Chutintorn Sriphrapradang, et al.
Published: (2025-06-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
by: Ioannis Ilias, et al.
Published: (2025-01-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Does Incretin Agonism Have Sustainable Efficacy?
by: Sok-Ja Janket, et al.
Published: (2024-11-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity
by: Vasco Sequeira, et al.
Published: (2025-04-01)

Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity
by: A. S. Ametov, et al.
Published: (2025-03-01)

Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
by: Sarah L Anderson
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)